Trial Profile

A Phase I Open-label Dose-finding Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of LXP1788 Injection in Patients with Advanced Solid Tumors.

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 01 Jul 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs LXP 108 (Primary)
Indications Solid tumours
Focus First in man; Pharmacokinetics
Sponsors LAUNXP Biomedical

Most Recent Events

05 May 2026 According to a LAUNXP Biomedical media release, the company has announced The safety review of the fourth dose group 0.72 mg/kg, once a week (QW) has been completed, and the trial has been successfully advanced to the next dose group.
05 May 2026 Results presented in the LAUNXP Biomedical Media Release.
24 Mar 2025 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com